Brief: Ascletis Announces Ind Approval Of Oral Viral Polymerase Inhibitor Asc10 For Monkeypox Indication By China Nmpa
26/01/2023 13:23
Jan 26 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ASCLETIS ANNOUNCES IND APPROVAL OF ORAL VIRAL POLYMERASE
INHIBITOR ASC10 FOR MONKEYPOX INDICATION BY CHINA NMPA
* ASCLETIS PHARMA- RECEIVED NOTICE OF ISSUANCE FROM USPTO
FOR
PATENT APPLICATION OF ASC10 & DERIVATIVES & THEIR USES TO TREAT
MULTIPLE VIRUS INFECTIONS
Source text for Eikon: ID:nPnfDl0la
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026